Biogen

Biogen Q4 Earnings Beat Expectations, 2026 Profit Outlook Strong

生化基因

Biogen Q4 revenue $2.3bln, FY25 revenue $9.9bln, exceeding guidance.

Biogen Exceeds Q4 Earnings and Revenue Estimates, Sets 2026 Outlook

Biogen's 15min chart triggers Bollinger Bands narrowing, KDJ death cross signal.

Biogen Triggers MACD Death Cross, KDJ Death Cross in 15-Minute Chart

Catalyst<ul> <li>Recent Marubozu White signals indicate strong closing momentum, suggesting potential for price consolidation or rebound.</li></ul>Risk<ul> <li>Bearish Engulfing patterns and overall weak technical indicators highlight significant downward pressure and risk of further decline.</li> <li>Fund flows show consistent outflows across all order sizes, indicating lack of institutional or retail buying interest.</li> <li>Analyst ratings are split between Buy and Neutral, reflecting a lack of consensus and weak institutional optimism.</li></ul>

Key Factors

Biogen announced clinical benefits of a high-dose nusinersen regimen for SMA patients in a Phase 2/3 DEVOTE study. Biogen's Head of Development, Singhal Priya, sold 1,330 shares at prices ranging from $179.3 to $179.89 between January 30 and February 2, 2026. Biogen is scheduled to report Q4 and full-year 2025 earnings on February 6, with potential offset from new drugs to counter declining MS drug sales.

BIIB News